FunPep Company Limited (4881.T)
Tokyo · JPY · Healthcare · Biotechnology
¥42 (-2.33%) as of
Key statistics
- Market cap
- 2.13B
- Forward P/E
- -1.29
- EPS (TTM)
- -37.71
- Dividend yield
- 0.00%
- 52-week range
- 41.00 – 130.00
- Beta
- 0.84
- Revenue (TTM)
- 1M
- Profit margin
- 0.00%
- Volume
- 129.10k
About FunPep Company Limited
FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices in Japan and internationally. The company develops SR-0379, a functional peptide which is in Phase III clinical trial for the treatment of skin ulcer; FPP003, an antibody-inducing peptide which is in Phase II clinical trial for the treatment of psoriasis and ankylosing spondylitis; FPP004X, an antibody-inducing peptide which is in Phase I clinical trial for the treatment of pollinosis; and FPP005, an antibody-inducing peptide which is in pre-clinical trial stage for the treatment of psoriasis. It is also involved in the development of Curepeptin, an antimicrobial peptide that disrupts bacterial cell membranes. The company was incorporated in 2013 and is headquartered in Ibaraki, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Ibaraki, Japan
- Employees
- 15
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.